DOCSLIB.ORG

T. Franklin Williams Scholars Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
T. Franklin Williams Scholars Program Developing a New Generation of Medical Subspecialists with Expertise in Aging and Care of the Elderly T. Franklin Williams Scholars Program Report to T. Franklin Williams Scholars Program Evaluation Team ASP Geriatrics Steering Committee Integrating Geriatrics Project Evaluation Team May 2011 Submitted by: Erika D. Tarver Project Administrator Association of Specialty Professors 330 John Carlyle Road Suite 610 Alexandria, VA 22314 T: (703) 341-4540 F: (703) 519-1890 [email protected] Kevin P. High, MD Principal Investigator William R. Hazzard, MD Co-Principal Investigator Table of Contents Narrative Progress Report Application and Award Progress Summary of Success of T. Williams Scholars Program Appendices A. 2008 Scholars 24-Month Progress Reports Neena S. Abraham, MD (Note: This is Dr. Abraham’s final report) Steven G. Coca, DO Jeffrey G. Horowitz, MD Danelle F. James, MD Heidi Klepin, MD George C. Wang, MD 2009 Williams Scholars Progress Reports and Summary of 18-Month Questionnaire B. Peter Abadir, MD 12-month Progress Report C. Kathleen M. Akgun, MD 12-Month Progress Report Publication D. Alison Huang, MD 12-Month Progress Report Publication E. Eswar Krishnan, MD 12-Month Progress Report Publication F. Rohit Loomba, MD Publication G. Sharmilee Nyenhuis, MD 12-Month Progress Report Publication H. Peter P. Reese, MD 12-Month Progress Report Publication I. Erik B. Schelbert, MD 12-Month Progress Report Publication J. Helen Keipp Talbot, MD 12-Month Progress Report Publication K. Summary of 18-Month Questionnaire 2010 Williams Scholars Mentor Interviews and Summary of Six-Month Questionnaire L. Kellie Hunter-Campbell, MD Six-Month Mentor Interview M. Jessica Chia, MD Six-Month Mentor Interview N. Seong H. Cho, MD Six-Month Mentor Interview O. Vera Luther, MD Six-Month Mentor Interview P. Una E. Makris, MD Six-Month Mentor Interview Q. Alexander K. Smith, MD Six-Month Mentor Interview R. Michael E. Widlansky, MD Six-Month Mentor Interview S. Summary of Six-Month Questionnaire T. Grants for Early Medical/Surgical Specialists’ Transition to Aging Research Funding Opportunity Announcement T. Franklin Williams Scholars Program Evaluation Report The Association of Specialty Professors (ASP)—the organization of specialty internal medicine divisions at medical schools and community teaching hospitals in the United States and Canada—created the T. Franklin Williams Scholars Program to improve the care of older adults by identifying, training, and developing a cadre of leaders specifically focused on researching the geriatric aspect of their subspecialty. There are currently two award structures for the T. Franklin Williams Scholars Program. Through the first structure, ASP and its partners provide two- to four-year development awards for internal medicine junior faculty at the early stages of their academic career. The total amount of the award varies from $75,000 to $225,000, and it supports the applicants’ research and career development. The second structure of the Williams Scholars award is offered in collaboration with the National Institute on Aging (NIA) through the Grants for Early Medical/Surgical Subspecialists’ Transitions to Aging Research (GEMSSTAR) award program. The GEMSSTAR award, which utilizes the R03 award mechanism, will provide successful applicants up to $100,000 to support research in a geriatric aspect of their internal medicine or surgical subspecialty. To provide opportunities for professional and career development, ASP and its partners will offer the Williams Scholars awards to those GEMSSTAR applicants who have received a fundable score on their application. The Williams Scholars career development awards support applicants’ plans for continued involvement in geriatrics activities or development of research skills (i.e., master’s level coursework in statistical analysis). Similar to the first structure, the Williams Scholars awards provide recipients with two-years of career development support. The total amount of the award is $50,000. For the purpose of this evaluation report, ASP is only evaluating the first structure for the T. Franklin Williams Scholars awards and will provide a summary of the administration of the second award structure. Methods ASP evaluates the success of the T. Franklin Williams Scholars Program through scholar questionnaires, scholar progress reports, and mentor interviews. Williams Scholars are required to submit 12- and 24-month research and career development progress reports to ASP and the sponsoring specialty societies. In addition to the progress reports, ASP asks the scholars to complete questionnaires at six and 18 months. Through these questionnaires, ASP gathers specific information about the publication and presentation of the recipients’ research, the status of grants the award recipients have applied for, and their roles in educating others about a geriatric aspect of their subspecialty. Progress reports for the 2008 and 2009 Williams Scholar are included as appendices of this report. A summary of the scholars’ questionnaires is included in this report. In addition to the above, ASP interviews the geriatrics and research mentors of the 2010 Williams Scholar at six months into the award. Mentors are asked about the progress of the scholars’ research and career development plans as well as the scholar’s commitment to research and education in the geriatric aspect of his or her specialty. Mentors are also asked to identify challenges or advantages that may affect the goals of the research project, comment on how the program has helped the award recipient in his or her professional development, and rate the scholar’s success in comparison to other faculty at a similar stage of career development. Lastly, the mentors are asked about their role in helping the scholar implement his/her career development plan and reach independent investigator status. The mentor interviews for the 2010 Scholars are included in the appendices of this report. Quantitative Results Out of the 18 possible responses, 16 Williams Scholars from the 2009 and 2010 cohorts completed the six- and 18-month questionnaires. From those responses, 10 scholars have published a peer-reviewed article. In addition, seven of the 16 scholars presented on their research at a workshop or professional conference within the last year, 11 also applied for or received a grant from the National Institutes of Health in the last 12 months. Seven Scholars out of the 16 also reported involvement in a Claude D. Pepper Older Americans Independence Center, John A. Hartford Foundation Center of Excellence, or a Department of Veterans Affairs’ Geriatric Research Education and Clinical Center. In an effort to measure the long-term success of the T. Franklin Williams Scholars Program, ASP tracks the success of Williams Scholars through the collection of curriculum vitae, publication searches on PubMed, and National Institutes of Health (NIH) funding searches via the NIH Research Portfolio Online Reporting Tools Expenditures and Results database. Out of 82 T. Franklin Williams Scholars from the 2002-2010 cohorts, 43 scholars obtained extramural funding from NIH that exceeds $40 million dollars. A breakdown of the extramural funding by specialty and NIH institute or center is in Appendix x. Qualitative Results Interviews conducted with the scholars’ geriatrics and research mentors offered additional insight on the progress, successes, and challenges faced by the 2010 Scholars. Based on the interviews, most of the scholars have started working on applications for a K08 or a K23 award, including the Paul B. Beeson Career Development Award. Since the interview was conducted during the first nine months of awards, most mentors felt that Scholars did not have the analyzed or published data to be considered a competitive applicant for an independent investigator award. However, most of the mentors felt that with the protected time from the Williams Scholars award, and the research support, that most Scholars will be ready to apply for an R01 award by the end of the Williams Scholars award (June 30, 2013). While highlighting the successes of the scholars, it is also important to recognize the challenges they face. A challenge that several scholars faced was with their collaborations with both internal and external stakeholders (e.g., institution center on aging and Kaiser Permanente). The challenges they face with the two stakeholders is navigating the political process of research collaborations. With internal stakeholders, the scholars’ project may be delayed because it is not considered as high a priority as other senior investigators’ projects. With external stakeholders, the scholar’s project may be delayed because the research question does not align with the stakeholder’s actual practices (e.g., trying to capture data that is not being tracked in a systematic manner). To work through that, the scholars are working with their established research and geriatrics mentors to help navigate the political processes of collaborating with various stakeholders so their project is not delayed. Administration The award application and selection process is now underway for the 2011 award cycle. The 2011 awards will be offered in collaboration with the NIA GEMSSTAR award program. The partners for the 2011 cycle are: • The American Academy of Allergy, Asthma, and Immunology (AAAAI). • The American College of Rheumatology Research and Education Foundation (ACR REF). • The American Diabetes Association (ADA). • The American Geriatrics Society
Load more

Recommended publications
  • Journal Pre-Proof
    Journal Pre-proof Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. Jaworski PII: S2319-4170(20)30209-2 DOI: https://doi.org/10.1016/j.bj.2020.11.011 Reference: BJ 374 To appear in: Biomedical Journal Received Date: 2 September 2020 Revised Date: 6 November 2020 Accepted Date: 22 November 2020 Please cite this article as: Jaworski JP, Neutralizing monoclonal antibodies for COVID-19 treatment and prevention, Biomedical Journal, https://doi.org/10.1016/j.bj.2020.11.011. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Chang Gung University. Publishing services by Elsevier B.V. TITLE: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. JAWORSKI Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina KEYWORDS: SARS-CoV-2, Coronavirus, Monoclonal Antibody, mAb, Prophylaxis, Treatment CORRESPONDING AUTHOR: Dr. Juan Pablo Jaworski, DVM, MSc, PhD. Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria Las Cabañas y de los Reseros (S/N), Hurlingham (1686), Buenos Aires, Argentina Tel / Fax: 054-11-4621-1447 (int:3400) [email protected] ABSTRACT The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
    [Show full text]
  • HIV?AIDS Researchers at the NIH Clinical Center
    The NIH Clinical Center treats a diverse group of patients from all over the world. It also draws researchers from different cultures and backgrounds. Learn more about some of the many researchers who conduct their work on the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the Clinical Center. Thomas C. Quinn, M.D., M.Sc., conducts research for the National Institute of Allergy and Infectious Diseases at the NIH Clinical Center. He is a senior investigator and chief of the International HIV/STD Section of the Laboratory of Immunoregulation. Dr. Quinn obtained his M.D. from Northwestern University. He was a research associate in infectious diseases in the NIAID Laboratory of Parasitic Diseases and completed a fellowship in infectious diseases at the University of Washington. Since 1981, he has been assigned to the division of infectious diseases at Johns Hopkins University, where he became a professor of medicine in 1991. Dr. Quinn is a member of the Institute of Medicine and the National Academy of Sciences and is a fellow of the American Association for the Advancement of Science. His major areas of research are: Definition of epidemiologic features of HIV-1 and HIV-2 infections in developing countries and the United States Assessment of biomedical interventions to control HIV, including circumcision, prevention of mother-to-child transmission, pre-exposure prophylaxis, and vaccine development Assessment of the frequency of Chlamydia trachomatis infections in selected populations using noninvasive sensitive nucleic-acid amplification assays for diagnosis Evaluations of interventions to control blinding trachoma due to Chlamydia trachomatis in sub-Saharan Africa See the full program description.
    [Show full text]
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The
    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
    [Show full text]
  • Nci-Plan-2013.Pdf
    THE NATIONAL CANCER PROGRAM MANAGING THE NATION’S RESEARCH PORTFOLIO AN ANNUAL PLAN AND BUDGET PROPOSAL FOR FISCAL YEAR 2013 National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Contents 1 Foreword 4 Provocative Questions 8 Center for Cancer Genomics 16 Introduction to Cancer Profiles 18 Pancreatic Ductal Adenocarcinoma 22 Colorectal Cancer 26 B-Cell Lymphoma 30 Renal Cell (Kidney) Cancer 34 GI Stromal Cancer 39 Research Focus: Comorbidities 42 Research Focus: Circulating Tumor Cells 44 Research Focus: Reducing Cancer Health Disparities 50 The Frederick National Laboratory for Cancer Research 61 Small Business Innovation Research, Small BusinessTechnology Transfer (SBIR, STTR) 66 NCI Center for Global Health 72 NCI-Designated Cancer Centers 83 Glossary of Terms 84 Budget FOREWORD The National Cancer Program MANAGING THE NATION’S RESEARCH PORTFOLIO his year marks the 75th anniversary of the founding of the National Cancer Institute, the first so-called “categorical institute” of what has become the National Institutes of Health, with its 27 Institutes and Centers. Over the years, the Congress and the public have generously supported the TNCI—and the NIH generally—with sustained budgetary increases. This was especially true for the NCI during the rapid expansion of its budget following the National Cancer Act of 1971 and for the NIH, including the NCI, during the 5-year doubling of its budget, launched in 1998. Both of these eras of rapid growth were remarkably fruitful. The first launched the pursuit of cancer genes and the molecular basis of oncogenesis, laying the foundation for the transformation of clinical oncology that is now occurring.
    [Show full text]
  • NIHAA Update 1Velco111es Lerters and Eastern Europe and at the Undergradu­ 1968, a Period of Considerable Growth News from Its Readers
    The Newsletter of the L NIH Alumni Association Summer 1999 Vol. 11, No. 2 date NIHAA Members Enjoy June Annual Meeting with Henney, Morella Alumni attendi ng the 1999 annual meeting of the NIH.AA were given a first-band briefing on FDA by Dr. Jane E. Henney, the receml y appointed FDA commissioner. Tbe audience also participated in a question and answer exchange witb Rep. Constance A. Morella (R-Md.), who was presented with tbe NIHAA 1999 Public Service Award. Almost I00 alumni attended the June 12 morning meeting at the Mary Woodard Lasker Center on the NIH campus. Henney, wbo was NCI deputy director for five of her lO years at NIH (1985-1995) spoke infonnalJy on some of FDA's principal concerns at this time: the agency's efforts to speed Shown at the NIHAA annual meeting are (from I} NIH alumna Dr. Jane E. Henney, FDA up review without sacrifice of quality commissioner, who spoke on "Back Home Again via Indiana, Kansas and New Mexico," and safeguards; tbe need for recruiting Dr. John F. Sherman, Rep. Constance A. Morella (R-Md.), who received the 1999 NIHAA Public Service Award, and Dr. William S. Jordan, Jr., outgoing NIHAA president. (see A flflual Meeting, p. 12) Director's Advisors Bat 6 for 7 in June Meeting In This Issue Page Choppin To Give Third Research Festival '99 J By Rich McManus NIHAA Shannon Lecture Ca/e11dar 5 The scorecard at the end of a daylong Dr. Purnell W. Cboppin, president of .News .from a11d about Nlf/A;/ me111be1:r (f session of lhe advisory committee to the Howard Hughes Medical lnstirure, the NIH director (ACD) on June 3 read A le11erjro1111he 11e111 Nlf/AIJ preside111 IO will deliver the third James A.
    [Show full text]
  • Study Protocol, Including Amendment
    Document Type: Study Protocol, including Amendment (Informed Consent Template located in Appendix I of the Protocol Version 1.0 and Version 2.0) Official Title: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults NCT Number: NCT03478891 Document/Date: Protocol Amendment Version 2.0: April 6, 2018 Protocol Version 1.0: February 21, 2018 Version 2.0 April 6, 2018 VACCINE RESEARCH CENTER Protocol VRC 608 (NIH 18-I-0069) A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF A HUMAN MONOCLONAL ANTIBODY, VRC-EBOMAB092-00-AB (MAB114), ADMINISTERED INTRAVENOUSLY TO HEALTHY ADULTS Study Product Provided by: Vaccine Research Center (VRC) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Bethesda, MD Clinical Trial Sponsored by: NIAID/VRC/NIH, Bethesda, Maryland IND 138,090 Sponsored by: VRC/NIAID/NIH, Bethesda, Maryland Principal Investigator: Martin Gaudinski, MD VRC/NIAID/NIH Bethesda, MD 20892 IRB Initial Review Date: January 8, 2018 PRODUCT: VRC-EBOMAB092-00-AB (MAb114) PROTOCOL: VRC 608, VERSION 2.0 PROTOCOL DATE: APRIL 6, 2018 TABLE OF CONTENTS Page ABBREVIATIONS....................................................................................................................... 5 PRÉCIS.......................................................................................................................................... 8 1. INTRODUCTION............................................................................................................
    [Show full text]
  • See the Vaccine Research Center Brochure
    Vaccine Research Center NIAID National Institute of Allergy and Infectious Diseases U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Letter from John R. Mascola, M.D., NIAID Vaccine Research Center Director, and Anthony S. Fauci, M.D., NIAID Director The Dale and Betty Bumpers Vaccine Research Center (VRC) was created by Presidential Executive Order in 1997 to accelerate the development of a vaccine directed against the devastating global pandemic caused by HIV. The VRC began its vital HIV work in 2000 and has since further expanded its scope and capabilities to combat other high-burden diseases such as influenza, respiratory syncytial virus (RSV), malaria, and tuberculosis, as well as biodefense threats and emerging infectious diseases, including Ebola, chikungunya, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), West Nile, and Zika. As an intramural research arm of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), the VRC is led by an integrated team of specialists in various disciplines, including immunology, virology, structural biology, and bioengineering. By encompassing these scientific disciplines under one roof, together with the capability to conduct human clinical trials, the VRC accelerates the process of scientific discovery leading to the design and development of prototype vaccines and biologics to protect against infectious diseases. The VRC operates as the closest analog at NIH to a private
    [Show full text]
  • Vaccine Research Center, NIAID, NIH
    4/17/2018 PIPELINE OF HIV MONOCLONAL ANTIBODIES FOR PREVENTION OF HIV Session on Antibody‐Mediated Prevention 2018 Global Vaccine and Immunization Research Forum (GVIRF) 20‐22 March 2018 Bangkok, Thailand Barney S. Graham, MD, PhD Deputy Director Vaccine Research Center, NIAID, NIH Dale and Betty Bumpers Vaccine Research Center Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health 2017 VRC Principal Investigators and Program Directors 1 4/17/2018 VRC Research & Development: From AIDS to Zika August 2000 AIDS/HIV Chikungunya Ebola/Marburg Influenza Malaria MERS-CoV, SARS RSV Smallpox Tuberculosis W/E/V equine encephalitis viruses West Nile virus, Zika Engineering Lab Pilot Plant Vaccine Evaluation Clinic Immunology Lab Partners for Advanced Development Functional Activity of Anti-Viral Antibodies • Neutralization – Aggregation – Attachment blocking – Cleavage inhibition – Fusion inhibition – Preventing particle release • Fc‐mediated functions – Antibody dependent cell‐mediated cytotoxicity (NK, Macrophage, Neutrophil) – Complement binding and activation • Opsinization and clearance by non‐susceptible cells • Blocking pathogenic immunomodulatory molecules 2 4/17/2018 Long History of Using Antibodies to Treat Infectious Diseases (Serum Therapy) Shibasaburo Kitasato 1890: Emil von Behring and Shibasaburo Kitasato worked on “anti‐ toxins” for tetanus and diphtheria that led to concept for serum therapy 1901: Emil von Behring ‐ 1901 Nobel Prize in Physiology or Medicine “For his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of Wernicke, Frosch, and medical science and thereby placed in the hands of the physician a Behring in Koch’s Berlin Lab victorious weapon against illness and deaths".
    [Show full text]
  • Conversations with Mike Milken
    CONVERSATIONS WITH MIKE MILKEN Francis Collins Director, National Institutes of Health April 3, 2020* Mike Milken: Good morning, Francis. Francis Collins: Good morning, Mike. One of the things we learned many years ago is that to accelerate science, one of the keys was collaboration. Could you talk a little bit about how you feel collaboration is working today? Well, it is critical, especially at a time of global pandemic with COVID-19 that we see around us. For me, having come up through scientific experiences like the Human Genome Project and various things that followed after that, all of which are intensely collaborative, it’s natural to look at “Are we really doing everything we can this situation and say, are we doing in this moment of global crisis to knock enough to bring together all of the down barriers and accelerate progress?” best and brightest; all the talent; all the resources from every sector; from academia; from NIH; from industry, both pharma and biotech; from philanthropy; This interview has been lightly edited for clarity and readability. Conversations with Mike Milken 1 Conversations with Mike Milken: Francis Collins, April 3, 2020 from stakeholders of all sorts; from the regulators? Are we really doing everything we can in this moment of global crisis to knock down barriers and accelerate progress? So that's where my head is this morning, sequestered as I am in my home office trying to behave the way we all should be in terms of distancing, but trying to light a fire under any kind of opportunity here to speed up the process of identifying effective treatments and vaccines and making sure our clinical trials are ready and tuned up, to try out virtually all of the good ideas that come along.
    [Show full text]
  • Paving the Road to an HIV Vaccine
    Paving the Road to an HIV Vaccine: Employing Tools of Public Policy to Overcome Scientific, Economic, Social and Ethical Obstacles Michael Langan and Chris Collins Monograph Series December 1, 1998 Center for AIDS Prevention Studies AIDS Research Institute University of California, San Francisco This research was supported by the National Institute of Mental Health, National Institutes of Health, grant number MH42459. PAVING THE ROAD TO AN HIV VACCINE TABLE OF CONTENTS PREFACE..........................................................................................................................................3 THE GLOBAL TRAGEDY OF HIV DEMANDS A PREVENTATIVE VACCINE .......................................4 NEW GOVERNMENT PROGRAMS AND FUNDS ..................................................................................5 National Institutes of Health.........................................................................................................5 NIH AIDS Research Program Evaluation Task Force ....................................................................5 AIDS Vaccine Research Committee.............................................................................................5 NIH Office of AIDS Research.......................................................................................................6 Vaccine Research Center............................................................................................................6 The National Institute of Allergy and Infectious Diseases...............................................................6
    [Show full text]
  • Annual Report FY 2020
    NIH Technology Transfer Annual Report FY 2020 FY 2020 NIH Technology Transfer Annual Report 1 TABLE OF CONTENTS Introduction .............................................................................................................. 4 Mission Statement ................................................................................................... 5 Inventions and Agreements ................................................................................... 6 Institute and Center Updates .................................................................................. 9 NCATS - National Center for Advancing Translational Sciences ............................................. 9 NCI - National Cancer Institute................................................................................................11 NHGRI - National Human Genome Research Institute .......................................................... 16 NHLBI - National Heart Lung and Blood Institute ................................................................... 18 NIAID - National Institute for Allergies and Infectious Diseases ............................................. 22 NIDDK - National Institute of Diabetes and Digestive Diseases ............................................ 26 NIEHS - National Institute of Environmental Health Sciences ............................................... 27 NIMH - National Institute of Mental Health ............................................................................. 29 NINDS - National Institute of Neurological Disorders
    [Show full text]
  • Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations for Fiscal Year 2014
    DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION, AND RELATED AGENCIES APPROPRIATIONS FOR FISCAL YEAR 2014 WEDNESDAY, APRIL 2, 2014 U.S. SENATE, SUBCOMMITTEE OF THE COMMITTEE ON APPROPRIATIONS, Washington, DC. The subcommittee met at 10 a.m., in room SD–192, Dirksen Sen- ate Office Building, Hon. Tom Harkin (chairman) presiding. Present: Senators Harkin, Durbin, Mikulski, Moran, Cochran, Shelby, and Kirk. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH STATEMENT OF FRANCIS S. COLLINS, M.D., PH.D., DIRECTOR ACCOMPANIED BY: ANTHONY S. FAUCI, M.D., DIRECTOR, NATIONAL INSTITUTE OF AL- LERGY AND INFECTIOUS DISEASES HAROLD E. VARMUS, M.D., DIRECTOR, NATIONAL CANCER INSTI- TUTE GARY H. GIBBONS, M.D., DIRECTOR, NATIONAL HEART, LUNG AND BLOOD INSTITUTE STORY C. LANDIS, PH.D., DIRECTOR, NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE CHRISTOPHER P. AUSTIN, M.D., DIRECTOR, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES OPENING STATEMENT OF SENATOR TOM HARKIN Senator HARKIN. The Appropriations Subcommittee on Labor, Health and Human Services, and Education, and Related Agencies will come to order. Good morning, everyone, and welcome. Sorry we are a little late. We had a vote at 10—that is all. Well, today will be my final Appropriations budget hearing for the NIH (National Institutes of Health) as the chair of this sub- committee. I took over this subcommittee from Senator Lawton Chiles in 1989. That is a long time ago it seems, a quarter century. I am so proud of all that we have done—all of us here—often on a bipartisan basis, to transform the National Institutes of Health into truly the jewel and the crown of biomedical research not only in the United States, but globally.
    [Show full text]